Develops nanomedicines for viral diseases, focusing on antiviral therapies and nanotechnology-based drug development.
NanoViricides, Inc. is a pioneering nano-biopharmaceutical research and development company focused on the discovery, development, and commercialization of innovative drugs for treating viral infections. Headquartered in Shelton, Connecticut, the company is dedicated to advancing a robust pipeline of nanoviricides aimed at addressing various viral diseases.
Among its key initiatives, NanoViricides is developing treatments such as Monkeypox Treatment for combating the Monkeypox virus, and Adenovirus 71 Treatment targeting severe pediatric hepatitis caused by Adenovirus 71 and related viruses. The company's HerpeCide Program Expansion includes a broad-spectrum approach to nanoviricide drugs designed to tackle different herpes viruses across multiple indications.
NanoViricides also focuses on developing FluCide, an injectable broad-spectrum anti-influenza nanoviricide for hospitalized patients, as well as an oral formulation for outpatient use. Additionally, the company is advancing Nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various types of Dengue viruses, and HIVCide, an escape-resistant anti-HIV nanoviricide. With a foundation established in 2005, NanoViricides continues to lead in the development of innovative therapies against a wide range of viral pathogens, positioning itself at the forefront of nanomedicine in the fight against infectious diseases globally.